| Japanese |
|---|
| Title | 111In-Antimyosin Fabを用いた心筋症における心筋障害の評価 |
|---|
| Subtitle | 《原著》 |
|---|
| Authors | 西村恒彦*, 永田正毅**, 植原敏勇*, 林田孝平*, 三谷勇雄*, 汲田伸一郎* |
|---|
| Authors(kana) | |
|---|
| Organization | *国立循環器病センター放射線診療部, **内科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 27 |
|---|
| Number | 6 |
|---|
| Page | 619-627 |
|---|
| Year/Month | 1990/6 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」111In-標識抗ミオシン抗体は心筋障害に特異的に集積するとされている. そこで, 本法を用いて心筋症における活動的な心筋障害を検出できないか臨床応用を行った. 対象は, (1)拡張型心筋症10例, (2)拡張相を示す肥大型心筋症7例および(3)対照8例である. 111In-antimyosin Fab 74 MBq(2 mCi)静注48時間後にplanarおよびSPECT像を撮像した. 視覚的に111In-antimyosin Fabの心筋集積を4段階(+3, +2, +1, 0)に分け, +2以上を陽性とした. また, 正面像にて心筋, 肺野に関心領域を設定し, 心筋/肺野集積比を算出した. 両者の相関は0.88と良好であった. 陽性像は, (1)9/10(90%), (2)7/7例(100%), および(3)0/8(0%)に認めた. 平均心筋/肺野集積比は, (1)2.04±0.24(2)2.46±0.49および(3)1.53±0.13であった. (1)では心不全合併例が多く, LVEFは低下していた. (2)では5例(71%)に血清CPK, LDHの上昇, タリウム欠損像があり, 心拡大, LVEFの低下を認めた. (1), (2)は予後不良の心疾患であり, 本法は徐々に崩壊する心筋壊死を検出できる可能性があり, 心筋生検とは異なった診断情報を提供する可能性が示唆された. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 111In-antimyosin Fab, 201TlCl, Dilated cardiomyopathy, Dilated phase of hypertrophic cardiomyopathy. |
|---|
| English |
|---|
| Title | Assessment of Myocardial Damage in Cardiomyopathy Using 111In-Antimyosin Fab Myocardial Scintigraphy |
|---|
| Subtitle | - Original Articles - |
|---|
| Authors | Tsunehiko NISHIMURA, Seiki NAGATA, Toshiisa UEHARA, Kohei HAYASHIDA, Isao MITANI, Shinichiro KUMITA |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Radiology and Department of Cardiology, National Cardiovascular Center |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 27 |
|---|
| Number | 6 |
|---|
| Page | 619-627 |
|---|
| Year/Month | 1990/6 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | 111In-antimyosin Fab (AM) myocardial scintigraphy was carried out in (A) 10 patients with idiopathic dilated cardiomyopathy, (B) 7 with dilated phase of hypertrophic cardiomyopathy and (C) 8 with normal (control) individuals. Imaging was taken 48 hours after intravenous injection of 74 MBq of AM. Myocardial uptake of AM was evaluated qualitatively and quantitatively. Positive uptake was observed in 9/10 (90%), 7/7 (100%) and 0/8 (0%) in group A, B and C, respectively. AM index (heart/lung ratio) in group A and B were 2.04+-0.24 and 2.46+-0.49, values significantly higher than that obtained in the control patient without cardiomyopathy (1.51+-0.13) (p<0.01). Positive monoclonal antimyosin sntibody studies were highly prevalent in dilated cardiomyopathic and dilated phase of hypertrophic cardiomyopathic patients, even in the presence of negative right ventricular biopsy. It is suggested that this method was useful for the noninvasive assessment of active myocardial damage in these patients. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 111In-antimyosin Fab, 201TlCl, Dilated cardiomyopathy, Dilated phase of hypertrophic cardiomyopathy. |
|---|